The company has hired Brooklyn, NY-based ingredients distributor Nutribiolink to commercialize its fish oils in the U.S.
Omega-3 concentrates supplier KD Pharma (Bexbach, Germany) plans to increase market share in the U.S. dietary supplements market. The company has hired Brooklyn, NY-based ingredients distributor Nutribiolink to commercialize its patented, high-grade fish oils in the United States.
The company recently increased its production capacity to 2,000MT annually. Omega-3 concentrates are produced in a certified-GMP pharmaceutical facility.
KD Pharma’s patented kd-pür supercritical extraction process is said to enable a more-concentrated omega-3 fatty acid dose-up to 99% EPA and/or DHA-which it says exceeds concentrations possible using traditional methods. The kd-pür process employs dual technologies: supercritical CO2 fluid extraction and supercritical fluid chromatography. “This gives our customers the ability to decrease the delivery size for the same daily dosage, or to increase the dosage in the same soft-gel size, both lowering the manufacturing costs,” said Peter Lembke, KD Pharma’s vice president of sales and business development, in a press release.
Additionally, kd-pür gently extracts omega-3 fatty acids without applying excessive heat (<120° F). And the process works without chemical solvents or exposing oils to oxygen. “This does not only ensure the protection from oxidation of the product, but also from contamination from microorganisms that cannot survive in an oxygen-free atmosphere, as well as removing harmful substances such as contaminants, heavy metals, [and] PCBs,” Lembke said. kd-pür enables higher reproducibility and consistency from batch to batch, the company adds.
On the Nutribiolink partnership, Chris Hachey, KD Pharma’s director of sales and marketing, says, “We chose Nutribiolink to represent KD Pharma omega-3 oils in the U.S. not only because of their extensive industry contacts, but also because they have the technical knowledge that is required to promote high-grade fish oils.”
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.